Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Comment by Kayz88on Apr 20, 2024 3:23pm
286 Views
Post# 35999695

RE:RE:What price could Theralase fetch ?

RE:RE:What price could Theralase fetch ?The question becomes when will BTD come? I'm on the same boat regarding it being a great first step and should propel us to the dollar ranges. It was slated for Q1 and now Q2, but how confident are we that it'll be for Q3 or Q4? What caused the delay? No reason was officially communicated, we have a great number of bodies with a great number of theories that attributes to the FDA moving the goalpost or needing more patients. But until the company comes out and says: "Here are the issues that are causing the delay, here is how we are rectifying it" - I'm not gonna hold my breath. 
<< Previous
Bullboard Posts
Next >>